Shareholder Alert: Robbins LLP Reminds Investors Covetrus, Inc. (CVET) Sued for Making Misleading Statements
Shareholder Alert: Robbins LLP Reminds Investors Covetrus, Inc. (CVET) Sued for Making Misleading Statements
Shareholder rights law firmRobbins LLPreminds investors that a purchaser of Covetrus, Inc. (NASDAQ: CVET) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between February 8, 2019 and August 12, 2019. Covetrus operates as an animal-health technology and services company.
股东权益法公司Robbins LLPreminds Investors表示，Covetrus，Inc.(纳斯达克市场代码：CVeT)的一名买家在2019年2月8日至2019年8月12日期间提起集体诉讼，指控其违反了1934年证券交易法。番荔枝属(Covetrus)作为一家动物保健技术和服务公司运营。
If you suffered a loss as a result of Covetrus' misconduct,click here.
如果您因Covetrus的不当行为而蒙受损失，请单击此处。
Covetrus, Inc. (CVET) Accused of Misleading Shareholders
Covetrus，Inc.被控误导股东
According to the complaint, on April 23, 2018, Henry Schein announced the spin-off and merger of the Animal Health Business of Henry Schein with Vets First Choice ("VFC"). Covetrus shares began trading on February 8, 2019. Throughout the class period and in the Offering Documents for the spin-merger, Henry Schein highlighted Covetrus' strengths and touted Covetrus as a technology-enabled animal health business with a comprehensive service and technology platform and supply chain infrastructure. These benefits were reaffirmed later in Covetrus' financial reports and the Company reassured that the integration was "on track" to hit financial targets. However, in reality, Covetrus' strengths were overstated and the costs of the integration as well as the separation of Covetrus from Henry Schein had been much higher than represented. Then, on August 13, 2019, Covetrus shockingly reported a net loss of $0.09 per share rather than the expected increase of $0.17 per share and slashed its EBITDA guidance from estimates of $250 million to a realized $200 million. In its explanation, Covetrus confessed the undisclosed difficulties it was having in platform integration and separations costs from Henry Schein. Since this news, Covetrus' stock has plummeted with a decline of $9.71, or 42%, per share and currently trades at around $13.50.
起诉书称，2018年4月23日，Henry Schein宣布将Henry Schein的动物保健业务与兽医First Choice(VFC)分拆合并。Covetrus股票于2019年2月8日开始交易。在整个课程期间和分拆合并的招股文件中，Henry Schein强调了Covetrus的优势，并吹捧Covetrus是一家拥有全面服务和技术平台以及供应链基础设施的科技型动物保健企业。这些好处后来在Covetrus的财务报告中得到了重申，该公司保证，整合正在“轨道上”实现财务目标。然而，在现实中，Covetrus的优势被夸大了，而且Covetrus与Henry Schein的整合和分离的成本远远高于所表示的成本。然后，在2019年8月13日，Covetrus令人震惊地报告每股净亏损0.09美元，而不是预期的每股增加0.17美元，并将EBITDA指引从预期的2.5亿美元大幅下调至已实现的2亿美元。在解释中，Covetrus承认在平台集成和分离成本方面存在未披露的困难亨利·施恩(Henry Schein)。消息传出后，Covetrus的股价暴跌，每股下跌9.71美元，跌幅42%，目前股价约为13.50美元。
Covetrus, Inc. (CVET) Shareholders Have Legal Options
Covetrus，Inc.(CVeT)股东拥有法律选择权
Contact us to learn more:
联系我们了解更多信息：
Leo Kandinov
利奥·坎迪诺夫
(800) 350-6003
(800) 350-6003
lkandinov@robbinsllp.com
邮箱：lkandinov@robbinsllp.com
Shareholder Information Form
股东信息表
Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.Click Hereto receive free alerts from Stock Watch when companies engage in wrongdoing.
罗宾斯律师事务所(Robbins LLP)是全国公认的股东权利法领先者。该公司在股东衍生品和证券集体诉讼中代表个人和机构投资者，并帮助客户为自己和他们投资的公司实现了超过10亿美元的价值。单击此处可在公司从事不当行为时接收股票观察的免费警报。
Attorney Advertising. Past results do not guarantee a similar outcome.
律师广告。过去的结果并不能保证会有类似的结果。
View source version on businesswire.com:https://www.businesswire.com/news/home/20200211006113/en/
查看businesswire.com:https://www.businesswire.com/news/home/20200211006113/en/上的源代码版本
Contacts
联系人
Leo Kandinov
利奥·坎迪诺夫
Robbins LLP
罗宾斯律师事务所
5040 Shoreham Place
肖勒姆广场5040号
San Diego, CA 92122
圣地亚哥，钙 92122
lkandinov@robbinsllp.com
邮箱：lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
(619)525-3990或免费电话(800)350-6003
www.robbinsllp.com
Www.robbinsllp.com
译文内容由第三方软件翻译。